TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00077142 |
Recruitment Status :
Completed
First Posted : February 11, 2004
Last Update Posted : October 31, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Cancer | Drug: TAC-101 | Phase 1 Phase 2 |
OBJECTIVES:
Phase I
-
Primary
- Determine the maximum tolerated dose (MTD) of TAC-101 in patients with advanced hepatocellular carcinoma.
- Determine the safety of 2 consecutive courses of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the toxic and adverse effects profile of this drug in these patients.
Phase II
-
Primary
- Determine the objective antitumor response rate in patients treated with this drug at the MTD.
-
Secondary
- Determine the overall survival time of patients treated with this drug.
- Determine the time to disease progression in patients treated with this drug.
- Determine the duration of observed objective response, using WHO criteria and measurements of serum alpha-fetoprotein concentrations, in patients treated with this drug.
- Determine the time to treatment failure in patients treated with this drug.
- Determine the safety and tolerability of intermittent treatment with this drug in these patients.
OUTLINE: This is an open-label, dose-escalation study.
- Phase I: Patients receive oral TAC-101 once daily on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 6 patients receive escalating doses of TAC-101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
- Phase II: Patients receive oral TAC-101 at the MTD (determined in phase I) once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 35-60 days.
PROJECTED ACCRUAL: A total of 6-18 patients for the phase I portion and 21-41 patients for the phase II portion will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 37 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma |
Study Start Date : | April 2001 |
Actual Primary Completion Date : | July 2005 |
Actual Study Completion Date : | August 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: TAC-101
Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
|
Drug: TAC-101
Once daily by mouth on days 1-14, repeat every 21 days for 2 courses. |
- Maximum Tolerated Dose (MTD) of TAC-101 [ Time Frame: 60 Days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed hepatocellular carcinoma
- At least 1 previously unirradiated, bidimensionally measurable lesion greater than 20 mm by MRI or conventional CT scan OR at least 10 mm by spiral CT scan
- Patients with CNS involvement must have completed appropriate treatment and have no progressive neurologic deficits within the past 28 days
- No carcinomatous meningitis
PATIENT CHARACTERISTICS:
Age
- 18 to 80
Performance status
- ECOG 0-2
Life expectancy
- More than 12 weeks
Hematopoietic
- Hemoglobin ≥ 10.0 g/dL
- WBC ≥ 2,000/mm^3
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 40,000/mm^3
- No abnormal bleeding or clotting
Hepatic
- No grade C Child-Pugh cirrhosis
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Albumin ≥ 2.8 g/dL
- INR ≤ 1.5 times ULN
- Bilirubin ≤ 2.0 mg/dL
Renal
- Creatinine ≤ 1.5 times ULN
Cardiovascular
- No prior deep vein thrombosis
- No prior superficial venous thrombosis
- No family history of thromboembolism in a first-degree relative
- No lower extremity thromboses by Doppler ultrasound (unless a subsequent venous angiography confirms a false positive ultrasound)
Pulmonary
- No prior pulmonary embolism
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception, except oral contraceptives containing estrogen
- Fasting triglycerides ≤ 400 mg/dL for men or ≤ 325 mg/dL for women
- No other malignancy within the past 3 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix
- No uncontrolled metabolic disorders, other nonmalignant organ or systemic disease, or secondary effects of cancer that induce a high medical risk
- No known allergy or hypersensitivity to TAC-101 or its components
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior thalidomide
- No prior putative antiangiogenesis therapy
- Prior interferon allowed
Chemotherapy
- No more than 2 prior chemotherapy regimens
Endocrine therapy
- No concurrent estrogen products
Radiotherapy
- See Disease Characteristics
- More than 21 days since prior radiotherapy, except small portal radiotherapy used for the palliation of isolated, symptomatic, osseous metastases
- No prior radiotherapy to evaluable lesions
- No concurrent radiotherapy unless for bone pain that is present before beginning study
Surgery
- Not specified
Other
- Prior anticancer treatment allowed provided there is clear evidence of progressive disease after the most recent treatment
- More than 21 days since prior anticancer therapy and recovered
- No more than 2 prior treatment regimens
-
No concurrent therapeutic anticoagulants
- Concurrent low-dose warfarin for prophylactic care of indwelling venous access devices allowed
- No concurrent azoles or tetracyclines
- No concurrent medications known or suspected to increase risk of venous thromboembolism
- No other concurrent retinoids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00077142
United States, Texas | |
MD Anderson Cancer Center at University of Texas | |
Houston, Texas, United States, 77030-4009 |
Study Chair: | Melanie B. Thomas, MD | M.D. Anderson Cancer Center |
Publications of Results:
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00077142 |
Other Study ID Numbers: |
ID01-007 P30CA016672 ( U.S. NIH Grant/Contract ) MDA-ID-01007 ( Other Identifier: UT MD Anderson Cancer Center ) TAIHO-TAC101 NCI-1528 CDR0000349508 ( Registry Identifier: NCI PDQ ) |
First Posted: | February 11, 2004 Key Record Dates |
Last Update Posted: | October 31, 2018 |
Last Verified: | October 2018 |
advanced adult primary liver cancer recurrent adult primary liver cancer adult primary hepatocellular carcinoma localized unresectable adult primary liver cancer Oral TAC-101 |
Carcinoma Carcinoma, Hepatocellular Liver Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Adenocarcinoma Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |